AbbVie

News

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.

News

BeOne nears a possible FDA okay for sonrotoclax in mantle cell lymphoma, hoping to be the second BCL-2 inhibitor in the US after AbbVie's Venclexta.

News

Patients in the US and EU with follicular lymphoma have new treatment options, thanks to new approvals for CD20xCD3 bispecifics Lunsumio and Epkinly.

News

AbbVie has turned to an award-winning documentary director to help it highlight the lives of people living with chronic lymphocytic leukaemia.

News

Reports are emerging that a multibillion-dollar partnership between AbbVie and Calico has come to an end after more than a decade.

News

AbbVie has said it may not launch its ovarian cancer therapy Elahere in the UK if a viable NHS price cannot be agreed with NICE.